^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | PARG inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6184 / 13 - Pre-clinical study of SYX3759, a novel PARG inhibitor for the treatment of homologous recombination deficient malignancies
Published date:
03/15/2023
Excerpt:
Compared to PARPi, such as Olaparib, SYX3759 shows selective and potent cytotoxicity on a broader spectrum of homologous recombination deficient (HRD) tumors both in vitro and in vivo….Collectively, SYX3759 is a potent PARG inhibitor both in vitro and in vivo warranting future clinical trials for the treatment of HRD cancers and beyond.
